2014 is record year at Cooper

Friday, December 12 2014 | 00 h 00 min | Financial News

The Cooper Companies reported CA$1.95 billion in revenue for the 2014 fiscal year. This is a record for the company and is partly due to its acquisition of Sauflon in June 2014.

The CooperVision division’s revenue was CA$1.6 billion, up 10% from last year. In the fourth quarter, sales jumped 18% over 2013, to CA$442 million.

Fourth-quarter sales rose 13% for toric lenses, 26% for multifocals and 32% for single-use lenses, compared to 2013. Revenue in Europe, the Middle East and Africa increased by 43% over 2013, and represented 42% of total sales, compared to 40% for the Americas and 18% for Asia Pacific.

For further information: http://files.shareholder.com/downloads/COO/3707982498x0x798084/0b091a27-8896-4ee4-8f2b-f1e693fd3268/COO_News_2014_12_4_Earnings.pdf

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

2014 is record year at Cooper

Featured Posts